

South Australia

Trans-Tasman Mutual Recognition (South Australia) Regulations 2015

under the *Trans-Tasman Mutual Recognition (South Australia) Act 1999*

Contents

- 1 Short title
- 3 Interpretation
- 4 Temporary exemptions—synthetic drugs
- 5 Temporary exemption—MDMB-CHMICA
- 6 Temporary exemption—certain controlled drugs

Schedule 1—Temporary exemptions—synthetic drugs

Legislative history

1—Short title

These regulations may be cited as the *Trans-Tasman Mutual Recognition (South Australia) Regulations 2015*.

3—Interpretation

In these regulations—

Act means the *Trans-Tasman Mutual Recognition (South Australia) Act 1999*.

4—Temporary exemptions—synthetic drugs

- (1) For the purposes of section 5 of the Act and section 46 of the Commonwealth Act—
 - (a) the substances specified in Schedule 1 are declared to be exempt from the operation of the Commonwealth Act; and
 - (b) the provisions of the *Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014* inserted by the *Controlled Substances (Controlled Drugs, Precursors and Plants) Variation Regulations 2015* are declared to be exempt from the operation of the Commonwealth Act.
- (2) The exemptions from the Commonwealth Act under subregulation (1) have effect for a period of 12 months following the commencement of this regulation.

5—Temporary exemption—MDMB-CHMICA

- (1) For the purposes of section 5 of the Act and section 46 of the Commonwealth Act—
 - (a) the substance methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (MDMB-CHMICA) and any preparation containing that substance are declared to be exempt from the operation of the Commonwealth Act; and

- (b) the provisions of the *Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014* referring to the substance specified in paragraph (a) (inserted by regulation 4(4) of the *Controlled Substances (Controlled Drugs, Precursors and Plants) Variation Regulations 2015*) are declared to be exempt from the operation of the Commonwealth Act.
- (2) The exemptions from the Commonwealth Act under subregulation (1) have effect for a period of 12 months following the commencement of this regulation.

6—Temporary exemption—certain controlled drugs

- (1) For the purposes of section 5 of the Act and section 46 of the Commonwealth Act—
 - (a) the substances to which this regulation applies and any preparation containing 1 or more of those substances are declared to be exempt from the operation of the Commonwealth Act; and
 - (b) the provisions of the *Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014* referring to a substance to which this regulation applies (inserted by the *Controlled Substances (Controlled Drugs, Precursors and Plants) (Miscellaneous) Variation Regulations 2017*) are declared to be exempt from the operation of the Commonwealth Act.
- (2) The exemptions from the Commonwealth Act under subregulation (1) have effect for a period of 12 months following the commencement of this regulation.
- (3) This regulation applies to the following substances:
 - (a) acetyl fentanyl;
 - (b) butyryl fentanyl;
 - (c) clonazolam;
 - (d) deschloroetizolam;
 - (e) N,N-Dialkylaminocyclohexyl alkyl benzamides (not otherwise listed in Schedule 1 of the *Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014*);
 - (f) N,N-Dialkylaminocyclohexylmethyl alkyl benzamides (not otherwise listed in Schedule 1 of the *Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014*);
 - (g) 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700);
 - (h) diclazepam;
 - (i) fentanyls (not otherwise listed in Schedule 1 of the *Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014*);
 - (j) flubromazepam;
 - (k) flubromazolam;
 - (l) furanyl fentanyl;
 - (m) meclonazepam;
 - (n) nifoxipam;

- (o) ocfentanil;
- (p) para-fluorobutyryl-fentanyl;
- (q) pyrazolam.

Schedule 1—Temporary exemptions—synthetic drugs

- 1-pentyl-3-(Adamant-1-yl)indole (AB-001)
- N-(Adamant-1-yl)-1-(5-fluoropentyl)-1*H*-indole-3-carboxamide (STS-135)
- 3-(1-Adamantoyl)-indoles
- N-(1-Adamantyl)-1-(5-fluoropentyl)-1*H*-indazole-3-carboxamide (5F-AKB48)
- N-(1-Adamantyl)-indazole-3-carboxamides
- N-allyl-N-[2-(5-Methoxy-1*H*-indol-3-yl)ethyl]prop-2-en-1-amine(N,N-diallyl-5-Methoxytryptamine or 5-MeO-DALT)
- N-[1-Aminocarbonyl]-2-methylpropyl]-1-(cyclohexylmethyl)-1*H*-indazole-3-carboxamide (AB-CHMINACA)
- N-[1-(Aminocarbonyl)-2-methylpropyl]-1-pentyl-1*H*-indazole-3-carboxamide (AB-PINACA)
- N-[1-(Aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-1*H*-indazole-3-carboxamide (AB-FUBINACA)
- 1-(1,3-Benzodioxol-5-yl)-2-(ethylamino)propan-1-one (Ethylone)
- 1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one (Butylone)
- 1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one (Pentylone)
- 3,4 dichloro-N-[1-(dimethylamino)cyclohexylmethyl]benzamide (AH-7921)
- (3-Diethylamino-2,2-dimethylpropyl)-4-aminobenzoate (Dimethocaine)
- 6,7-dihydro-5*H*-cyclopenta[*f*][1,3]benzodioxol-6-amine (5,6-Methylenedioxy-2-aminoindane or MDAI)
- 2-(2,5-Dimethoxyphenyl)-*N*-(2-methoxybenzyl)ethanamine (25H-NBOMe)
- 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)
- 5-(1,1-dimethyloctyl)-2-[3-hydroxycyclohexyl]-phenol (cannabicyclohexanol)
- 5-(1,1-dimethylheptyl)-2-[3-hydroxycyclohexyl]-phenol (CP-47,497)
- 2-ethylamino-1-(4-methylphenyl)propan-1-one (4-methylethcathinone or 4-MEC)
- N-(1-Fenchyl)-indole-3-carboxamides
- 2-(4-Fluoro-2,5-dimethoxyphenyl)-1-aminoethane (2C-F)
- 2-(4-Fluoro-2,5-dimethoxyphenyl)-*N*-(2-methoxybenzyl)ethanamine (25F-NBOMe)
- Indazole-3-carboxamides
- (Indol-3-yl)-(2,2,3,3-tetra-alkylcyclopropyl)methanones
- Indole-3-carboxylic acid, quinolinyl esters

7-Methoxy-1-(2-morpholinoethyl)-N-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (N-Fenchyl-1-(2-morpholinoethyl)-7-methoxyindole-3-carboxamide or UR-12)

1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-propanone
(4'-Methyl- α -pyrrolidinopropiophenone or 4-MePPP or M α PPP)

Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (NM2201)

1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (alpha-PVP or alpha-pyrrolidinovalerophenone)

1-pentyl-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl-1H-indole-3-carboxamide (N-(1-Adamantyl)-1-pentyl-1H-indole-3-carboxamide or SDB-001 or APICA)

Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F-PB-22)

Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22)

Legislative history

Notes

- Please note—References in the legislation to other legislation or instruments or to titles of bodies or offices are not automatically updated as part of the program for the revision and publication of legislation and therefore may be obsolete.
- Earlier versions of these regulations (historical versions) are listed at the end of the legislative history.
- For further information relating to the Act and subordinate legislation made under the Act see the Index of South Australian Statutes or www.legislation.sa.gov.au.

Legislation revoked by principal regulations

The *Trans-Tasman Mutual Recognition (South Australia) Regulations 2015* revoked the following:

Trans-Tasman Mutual Recognition (South Australia) Regulations 2013

Principal regulations and variations

New entries appear in bold.

Year	No	Reference	Commencement
2015	188	<i>Gazette 23.7.2015 p3548</i>	23.7.2015: r 2
2015	244	<i>Gazette 3.12.2015 p5163</i>	3.12.2015: r 2
2017	305	<i>Gazette 7.11.2017 p4548</i>	12.11.2017: r 2

Provisions varied

New entries appear in bold.

Entries that relate to provisions that have been deleted appear in italics.

Provision	How varied	Commencement
<i>r 2</i>	<i>omitted under Legislation Revision and Publication Regulations 2002</i>	<i>3.12.2015</i>
r 5	inserted by 244/2015 r 4	3.12.2015
r 6	inserted by 305/2017 r 4	12.11.2017
<i>Sch 2</i>	<i>omitted under Legislation Revision and Publication Regulations 2002</i>	<i>3.12.2015</i>

Historical versions

3.12.2015